♥ HF Guideline NavigatorESC 2026

9 › 9.2

9.2 Chronic coronary syndromes

Pages 60–62 · open in PDF

Recommendations in this section

  • Class ILevel CCoronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and antianginal drugs, to relieve symptoms.
  • Class IIaLevel B1If revascularization is planned after assessment by a Heart Team, CABG should be considered as the preferred revascularization strategy, in patients with LVEF ≤ 35% and multivessel CAD suitable for surgery, to improve long-term survival.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 60 · PDF

VKAs in patients with HFd to prevent stroke and

thromboembolism. Rate control

Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.663,665 Digoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not

tolerated, in order to obtain short- and long-term rate control.665–667

Pacing indications in patients with HF do not differ from those without HF. However, long-term RV pacing can adversely impact LV function.706 In patients with HFrEF, where there is an expectation of high pacing requirements, i.e. complete heart block or AF with slow ventricular response, CRT implantation should be considered to improve outcomes (see Recommendation Table 7).409

Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical

limitations, recurrent HFH, and death.672,673 Intravenous amiodarone or digoxin may be

9.2. Chronic coronary syndromes

considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart

Obstructive CAD is a frequent cause of HF.33 Coronary microvascular dysfunction affects up to 80% of patients with HFpEF and seems to be associated with poor prognosis.707–709 Diagnostic work-up of chronic coronary syndromes in patients with HF is described in Section 5. Treatment of chronic coronary syndrom in patients with established HF is described below.

rate.668–671 Cardioversion Urgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm.669,671,692,695

Catheter ablation for AF should be considered in selectede patients with symptomatic AF and HFrEF to improve QoL and reduce the risk

of HFH or death.674–676,678,681,682,684,696 AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/ arterial thromboembolism (2 points), vascular disease, age 65–74 years; CRT, cardiac resynchronization therapy; DHF, decompensated heart failure; DOAC, direct-acting oral anticoagulant; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life; VKA, vitamin K antagonist. a Class of recommendation. b Level of evidence. c See Table 18. d Except for patients with moderate or severe mitral stenosis and in patents with mechanical prosthetic heart valves where VKAs are recommended. e All the following criteria are required: high burden AF, less than 1-year duration for continuous persistent AF, clear cause–effect relationship between AF and HF.

9.1.2. Ventricular arrhythmias Ventricular arrhythmias may cause HF or be a consequence thereof. In sustained ventricular tachycardia, initial management should include stabilization (electrical cardioversion), followed by identification and correction of precipitating factors, and optimization of FMT. Although amiodarone reduces ventricular arrhythmias, it does not reduce SCD or death.697 Patients with HF and resuscitated cardiac arrest or life-threatening ventricular arrhythmias have an indication for a secondary prevention ICD.119

Atrial fibrillation catheter ablation

Beta-blockers are recommended as first-line therapy in patients with HFrEF and CAD due to their prognostic effects, closely followed by other FMT drugs.288,290,291,710–712 Ivabradine should be considered in patients with HFrEF in sinus rhythm with heart rate >70 b.p.m. despite beta-blockers at the highest tolerated dose or if beta-blockers are contraindicated.294,713 Other medications such as amlodipine,714 felodipine,715 nicorandil,716 and ranolazine717 do not have effects on death but may improve symptoms. Trimetazidine may improve LV function and exercise capacity in patients with HFrEF and chronic coronary syndrome already on beta-blockers.718–720 Importantly, initiation and/or uptitration of antianginal therapy should not lead to reduction in FMT. Short-acting nitrates can cause hypotension and should be used with caution. Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) are not recommended in patients with HFrEF due to their negative inotropic effects which may precipitate the risk of HF events.721 The use of beta-blockers or calcium channel blockers do not appear to be associated with worse outcomes in HFpEF.722,723 Treatment of patients with HFpEF should be similar to that of patients without HF (see the 2024 ESC Guidelines for the management of chronic coronary syndromes).10

9.2.2. Myocardial revascularization Data to support the prognostic benefit of myocardial revascularization in patients with stable obstructive CAD and HF are limited. Two RCTs compared revascularization vs medical therapy in patients with LVEF ≤35% and multivessel coronary disease.178–180 The STICH trial compared coronary artery bypass grafting (CABG) to medical therapy and showed survival benefit

Heart failure can occur because of frequent PVCs.698 A burden of PVCs of about 10% precipitates an increased risk of HF and the risk increases with higher burden.119,699–701 Thus, regular assessment of LVEF in this setting is indicated. Amiodarone may be considered to reduce recurrent arrhythmias and improve LV function,697 with regular follow-up to assess possible side effects. Catheter ablation of PVCs may improve LV function and, possibly, outcomes in patients with PVCs.702–705 For further details, please refer to the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.119

DOACs are recommended in preference to

Page 61 · PDF

revascularization is planned, the multidisciplinary Heart Team should provide an individualized recommendation on the revascularization strategy—CABG or PCI—depending on patient characteristics. In case of persistent angina despite FMT for HF and antianginal drugs, revascularization is recommended regardless of LVEF. If the Heart Team agrees that revascularization is the best treatment option, in patients with HFrEF, LVEF ≤35% and multivessel disease, CABG should be the first choice (Figure 19). The Task Force recognizes an apparent discrepancy between the latter recommendation (class of recommendation IIa, level of evidence B1) and other recommendations in this context across other guidelines (e.g. 2024 ESC Guidelines for the management of chronic coronary syndromes, class of recommendation I, level

Figure 19 Management of coronary artery disease in patients with heart failure. BB, beta-blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Colours refer to class of recommendation. aExclusion of frailty, severe and multiple comorbidities and limited life expectancy making the risk of revascularization higher than the expected benefit. bPCI or continued medical therapy are alternative treatments if the patient is not eligible for CABG.

for CABG at long-term follow-up.179,180 The REVIVED-BCIS2 study compared percutaneous coronary intervention (PCI) and optimal medical therapy to optimal medical therapy alone and was neutral.178 The patient populations differed between the two trials and patients in REVIVED-BCIS2 were 10 years older, making comparison between them difficult. For details of these results and other studies, see Supplementary data online, Section S6.2.1.178,180,724–735 Patients with HF and chronic coronary syndrome due to obstructive CAD must receive FMT before revascularization. A multidisciplinary Heart Team discussion including an HF specialist is recommended to decide whether conservative treatment or an invasive treatment strategy should be adopted. If

Page 62 · PDF

control arm, mainly driven by WHF events.740 Therefore, treatment with a SGLT2-I is reasonable in these patients. Aortic valve intervention is recommended in all patients with HF and a life expectancy >1 year with high-gradient severe aortic stenosis, irrespective of LVEF, as well as in patients with severe low-flow low-gradient aortic stenosis and HFrEF. In patients with severe low-flow low-gradient aortic stenosis and HFpEF, aortic valve intervention should be considered. Details on diagnostic work-up, specific indications and the modality of intervention (TAVI vs surgery) are reported in the 2025 ESC/ EACTS Guidelines for the management of valvular heart disease.9

Recommendation Table 16 — Recommendations for revascularization in chronic coronary syndrome in patients with heart failure (see Evidence Table 82)

9.3.2. Aortic regurgitation

Severe aortic regurgitation can lead to LV dilatation and dysfunction which may progress to HF. Treatment with ACE-Is/ ARNIs/ARBs/MRAs while awaiting aortic valve intervention can be beneficial.741 Beta-blockers can prolong diastole and should be used only after careful consideration of risks and benefits. Specific recommendations for intervention are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9

Revascularization for symptom improvement (HFpEF and HFrEF) Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and

antianginal drugs, to relieve symptoms.734,735 Revascularization for outcome improvement (HFrEF)

9.3.3. Mitral regurgitation 9.3.3.1. Primary mitral regurgitation

If revascularization is planned after assessment

suitable for surgery, to improve long-term survival.180 CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. a Class of recommendation. b Level of evidence.

9.3. Valvular heart disease 9.3.1. Aortic stenosis Aortic stenosis can contribute to or cause HF by increasing LV afterload.736 Prevalence of aortic stenosis ranges between 3% and 7% in patients with chronic HF and is higher in patients with HFpEF as compared with those with HFrEF.737 About 50% of patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) have HF.738 Once HF symptoms develop, prognosis is poor and timely valve intervention is mandatory. HF therapies may be used cautiously and should not delay valve intervention. After valve intervention, a clinical and echocardiographic reassessment is important to detect residual HF or risk of HF readmission. In this regard, further optimization of FMT as well as treatment of comorbidities and management of procedure-related factors is appropriate.739 In the recent open-label DapaTAVI trial, 1222 patients with history of HF and at least one risk factor (diabetes, CKD, LV dysfunction) were randomly assigned to receive either dapagliflozin or standard of care. At 1-year follow-up, the risk of the primary endpoint (death from any cause or WHF events) was reduced by 28% in the treatment arm as compared with the

by a Heart Team, CABG should be considered as the preferred revascularization strategy, in patients with LVEF ≤35% and multivessel CAD

Primary MR is caused by abnormalities of the valve apparatus and can lead to HF. In severe primary MR with HF symptoms, surgical repair is preferred over replacement whenever feasible.739,742,743 Mitral transcatheter edge-to-edge repair (TEER) should be considered in patients at high surgical risk.9,744,745

9.3.3.2. Secondary mitral regurgitation Secondary or functional MR is primarily a disease of the left cardiac chambers rather than the valvular apparatus. It is common in patients with HF, especially those with HFrEF in whom the disease has a prevalence of 25%.746,747 In order to adequately assess the severity of MR, the patient should be euvolaemic or as close to euvolaemia as possible. The underlying aetiology and severity of MR needs to be assessed by cardiologists specialized in echocardiography and structural heart diseases.748 A new classification, differentiating between atrial secondary MR and ventricular secondary MR has been recently proposed.9 Atrial secondary MR can be associated with HFpEF.749 Indications for mitral valve treatment in atrial secondary MR are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9 In patients with severe ventricular secondary MR and HFrEF, optimization of FMT and GDIT with CRT implantation (if indicated) is mandatory before considering any mitral valve intervention (Figure 20). In case of concomitant CAD requiring revascularization, specific recommendations on management are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9 In selected patients without need for coronary revascularization, TEER is recommended. Table 19 provides the clinical and echocardiographic criteria for patient selection, which are based on inclusion criteria from RCTs. For the results of these studies, see Supplementary data online, Section S6.3.1.750–754 If the criteria reported in Table 19 are not fulfilled, other options can be considered. Specifically, in

of evidence B). However, the patient populations that were considered are slightly different in the chronic coronary syndrome guidelines (often patients with chronic coronary syndrome presenting with reduced LVEF) as compared to these guidelines (often patients with HFrEF presenting with CAD). In addition, according to the most recent system for level of evidence grading, proposed by the ESC, the Task Force considered STICHES, with all its limitations (mean age 60 years, limited number of events at 10 years, limited use of modern FMT), as the only possible study available to support the recommendation.180